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Abstract
Background: Human T-cell leukemia virus type 1 (HTLV-1) and type 2 both target T lymphocytes, yet induce
radically different phenotypic outcomes. HTLV-1 is a causative agent of Adult T-cell leukemia (ATL), whereas HTLV-2,
highly similar to HTLV-1, causes no known overt disease. HTLV gene products are engaged in a dynamic struggle
of activating and antagonistic interactions with host cells. Investigations focused on one or a few genes have
identified several human factors interacting with HTLV viral proteins. Most of the available interaction data concern
the highly investigated HTLV-1 Tax protein. Identifying shared and distinct host-pathogen protein interaction
profiles for these two viruses would enlighten how they exploit distinctive or common strategies to subvert cellular
pathways toward disease progression.
Results: We employ a scalable methodology for the systematic mapping and comparison of pathogen-host
protein interactions that includes stringent yeast two-hybrid screening and systematic retest, as well as two
independent validations through an additional protein interaction detection method and a functional
transactivation assay. The final data set contained 166 interactions between 10 viral proteins and 122 human
proteins. Among the 166 interactions identified, 87 and 79 involved HTLV-1 and HTLV-2 -encoded proteins,
respectively. Targets for HTLV-1 and HTLV-2 proteins implicate a diverse set of cellular processes including the
ubiquitin-proteasome system, the apoptosis, different cancer pathways and the Notch signaling pathway.
Conclusions: This study constitutes a first pass, with homogeneous data, at comparative analysis of host targets for
HTLV-1 and -2 retroviruses, complements currently existing data for formulation of systems biology models of
retroviral induced diseases and presents new insights on biological pathways involved in retroviral infection.
Keywords: HTLV, Interactome, Retrovirus, ORFeome, Tax, HBZ
Background
Human T-cell lymphotropic viruses HTLV-1 and -2 are
members of Deltaretrovirus genus of the Retroviridae
family [1]. HTLV-1 induces Adult T-cell Leukemia/Lym-
phoma (ATLL) [2], an aggressive lymphoproliferative dis-
ease. HTLV-1 is also associated with tropical spastic
paraparesis (TSP) [3], a neurological degenerative syn-
drome. HTLV-2 is closely related to HTLV-1 but causes
no known overt disease [4,5]. The elaborate pathogenicity
of HTLV-1 involves establishment and reactivation of
latent stages, transcriptional activation of specific cellular
genes, and modulation of cell death and proliferation path-
ways [6]. Modulations of viral and cellular function upon
infection rely on crosstalk between the few viral encoded
proteins and specific human proteins.
HTLV genomes encode structural proteins that form
the viral core particle (Gag and Env), and enzymatic ret-
roviral proteins (reverse transcriptase, integrase and
* Correspondence: marc_vidal@dfci.harvard.edu; jean-claude.twizere@ulg.ac.
be
1Center for Cancer Systems Biology (CCSB) and Department of Cancer
Biology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215,
USA
Full list of author information is available at the end of the article
Simonis et al. Retrovirology 2012, 9:26
http://www.retrovirology.com/content/9/1/26
© 2012 Simonis et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.protease). HTLV contain a cluster of alternatively
spliced open reading frames (ORFs) that encode regula-
tory proteins (Tax-1, Rex-1, HBZ, p30, p13, and p12 for
HTLV-1 and Tax-2, Rex-2, APH-2, p28, p11 and p10
for HTLV-2).
Investigations focused on one or a few genes have iden-
tified numerous human factors interacting with HTLV
viral proteins, with the results collected in several data-
bases: VirusMINT [7] and VirHostNet [8]. Most of the
available interaction data concern the highly investigated
HTLV-1 Tax protein. Few protein-protein interactions
(PPIs) have been reported for other HTLV-1 and HTLV-2
encoded proteins. Comparative molecular biology studies
of HTLV-1 and HTLV-2 have focused primarily on the
Tax oncoproteins [9,10]. Hence, many cellular proteins
and pathways exploited by these retroviruses to induce
disease are likely still unidentified. A systematic explora-
tion of shared and distinct host-pathogen protein interac-
tion profiles for these two viruses would likely identify
novel molecular mechanisms linked to HTLV infection
and be a useful tool for understanding how HTLV-1 sub-
verts cellular pathways toward disease progression.
Our high-throughput yeast two-hybrid (HT-Y2H) tech-
nology employs well-defined collections of cloned open
reading frames to provide systematic interrogation of
potential PPIs [11-14]. HT-Y2H is amenable for investigat-
ing pathogen-host interactions [15,16]. Here, we adapted
this strategy for the systematic mapping and comparison
of pathogen-host PPIs. We report viral-host interactome
maps for HTLV-1 and -2 retroviral proteomes with the
human proteome; we compare the spectra of host targets
for HTLV proteins and raise new hypotheses regarding
the pathogenic activities of HTLV-1.
Results and discussion
Identification of HTLV - human protein interactions
To identify retroviral PPIs with the human proteome we
adapted our well-established HT-Y2H system [12,14].
Using Gateway-based ORFeome libraries encoding
HTLV-1 and HTLV-2 proteins (HTLV-1 Gag, Pol, Rex,
Tax, Env, p12, p13, p30 and HTLV-2 Gag, Pol, Rex2,
Tax2, Env and APH-2 - Additional file 1: Table S1) in a
Y2H screen against the ~12,000 proteins expressed from
Human ORFeome v3.1 [17], we identified 1028 diploid
colonies representing 286 potential interactions between
human proteins and HTLV viral proteins. These interac-
tions were independently confirmed by pairwise Y2H
retesting [12].
HTLV structural and regulatory proteins have signifi-
cant sequence or functional similarity (for example
HTLV-1 Tax and HTLV-2 Tax share 77% of sequence
similarity, and both are transcriptional activators of viral
expression). These homologous viral proteins might
share one or more interacting partners amongst the
human proteins, interactions that were not identified in
initial screens because (i) highly overlapping or similar
viral ORFs may be misidentified with BLAST, and (ii)
interactions can be missed in a single screen [12,13,18].
We retested all homologous HTLV proteins for interac-
tion with each human protein found in our initial screen
with at least one homologous viral protein. For instance,
all human proteins identified as HTLV-1 Tax interactors
were also retested against HTLV-1 and HTLV-2 Tax
and Rex proteins (Additional file 1: Table S1). This
strategy combines the advantages of pooling [14] with
individual testing, to reduce the cost and workload of
the initial screen while keeping the ability to differenti-
ate similar proteins, overcome sensitivity and specificity
issues and permits comparison of negative results. The
final data set contained 166 interactions between 10
viral proteins and 122 human proteins (Figure 1 and
Additional file 1: Table S2). Among the 166 PPIs identi-
fied 87 and 79 interactions involved HTLV-1 and
HTLV-2 -encoded proteins, respectively. Twenty-eight
out of the one hundred and twenty-two human proteins
were found to interact with both viruses (Figure 1B).
In addition to applying stringent internal controls and
retests, to eliminate artifacts of the assay [19], we verified
the quality of our HT-Y2H results by applying a binary
interactome evaluation [12]. This evaluation employs
independent protein-protein interaction assays to mea-
sure how any PPI dataset performs relative to a positive
reference set (PRS) of high confidence manually curated
interactions from the literature versus a random refer-
ence set (RRS) and position our dataset compared to
these controls [12]. We tested 158 Y2H-identified binary
interactions by mammalian protein-protein interaction
trap assay (MAPPIT) [20]. MAPPIT is a forward mam-
malian two-hybrid strategy based on the activation of
type I cytokine-signaling pathway. To perform a MAPPIT
assay, we used as bait and prey, interacting partners fused
to a STAT recruitment-deficient homodimeric cytokine
receptor or to the C-terminal STAT3 recruitment por-
tion of the gp130 receptor, respectively. Interactions
between bait and prey proteins result in a functional
cytokine receptor monitored by a STAT3-responsive pro-
moter. The verification rate of our host-pathogen interac-
tome data set by MAPPIT was 29% (40/137 testable
pairs, Additional file 1: Table S2), which compares favor-
ably to PRS detection rates [18]. As for other PPI assays
tested so far, only a fraction of verifiable interactions
detected by one PPI method will retest positive with
another [18]. Previous studies show that MAPPIT detects
about 20%-25% of PRS pairs under conditions that mini-
mize the detection of RRS pairs [18]. As a control for
specificity, a random set of 40 proteins from the human
ORFeome 3.1 was also tested by MAPPIT for their inter-
action with HTLV proteins, and only 3 out of 40 (7.5%)
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Figure 1 Pipeline of the HT-Y2H experiment.( A) Retroviral ORFeome screened against Human ORFeome 3.1 in both configurations (DB-hORF
AD-rvORF and DB-rvORF AD-hORF). Interactions found in the primary screen were subjected to homologous individual retest, where any human
interactor of HTLV 1-2 protein was also retested for interaction with all homologous HTLV l and 2 proteins. An example of homologous group
with Tax and Rex is shown. To guarantee high specificity, only interactions identified with at least two out of three reporter phenotypes were
considered positive. (B) Venn diagram of the number of human proteins targeted by each virus.
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Page 3 of 20were found positive. The MAPPIT retest rate of our
HTLV-human PPIs represents ~80-100% of the maxi-
mum number of interactions expected to be recovered by
MAPPIT, with an estimated false positive rate of 0-20%
[12,13,18].
Human proteins interacting with viral proteins appar-
ently have significantly different topological properties
compared to random proteins in the human PPI network
[15,21]. Viral proteins seem to preferentially target “hubs,”
i.e. highly connected proteins in the human-human PPI
network. Preferential targeting of hubs is also observed in
our HTLV network (Table 1). Human targets of HTLV
proteins have higher connectivity (degree k = 13.75) com-
pared to the whole network (k = 3.79), are more centrally
located as measured by higher betweenness centrality
(BC), 12443 for viral targets vs 2208 for random proteins,
and have lower characteristic path length (CPL), 3.09 for
viral targets vs. 4.38 for random proteins.
Degree, Characteristic path length (CPL) and between-
ness centrality (Betweenness) for the 131 human proteins
identified in our screen (Viral Targets), the whole human
PPI network (Whole Network), and for human proteins
interacting with 19 random human proteins (Random
Sources). P-values assess the difference between viral tar-
gets and the whole network
As previously demonstrated and again confirmed here,
our Y2H methodology delivers high quality, reproducible
biophysical interactions [12-14], but there is no guarantee
that biophysical interactions are functionally relevant
in vivo. To functionally validate our PPI dataset, we rea-
soned that some human proteins interacting with viral
transactivators are likely to influence Tax transcriptional
activities and thus contribute to viral replication and
expression of cellular genes.
Many HTLV-human interactions in our data set (106/
166) involved the retroviral transactivator proteins
HTLV-1 Tax (57/166) or HTLV-2 Tax2 (49/166). To
examine the functional consequences of these associa-
tions, HEK293T cells were cotransfected with expression
vectors for Tax-1 and Tax-interacting proteins, together
with a firefly luciferase reporter driven by the HTLV-1
LTR promoter. As determined by normalized luciferase
reporter assays, we identified 31 proteins (37% of the 83
Tax-interacting proteins) that regulated HTLV-1 LTR
promoter activation by Tax (Figure 2 and Additional file
1: Table S3). There were 8 host factors that significantly
enhanced Tax transactivation activities suggesting their
potential implication in viral replication and persistence
in infected cells. Another group of 23 cellular proteins
down-regulated HTLV-1 LTR viral promoter activation
and as such may be implicated in the viral latency
which allows viruses to escape immune surveillance
(Figure 2 and Additional file 1: Table S3). We selected
two Tax1-cellular partners, SPG21, involved in the
repression of T cell activation [22], and FANCG, a DNA
damage response activated protein [23-25], for further
validation in a T lymphocyte cell line. We used Jurkat T
cells harboring a HTLV-1 LTR luciferase reporter (Jur-
kat-LTR-Luc) to confirm potential roles of SPG21 and
FANCG in viral replication. We transduced Jurkat-LTR-
Luc cells with a control shRNA and three validated
shRNAs directed against SPG21 or FANCG and mea-
sured luciferase reporter-expression and cell viability. In
accordance with regulation of Tax-transactivation data
(Figure 2 and Additional file 1: Table S3), knockdown of
SPG21 increased HTLV-1 LTR promoter activity while
depletion of FANCG decreased HTLV-1 LTR promoter
activity (Figure 3).
In summary, we identified 166 interactions between 10
viral proteins and 122 human proteins and verified their
overall quality through an independent assay. We func-
tionally validated our dataset by showing involvement of
31 human proteins in viral transcriptional regulation.
Analysis of the HTLV-1 and-2 interactome maps
Our standardized experimental conditions, which combine
stringent, high-throughput Y2H for a defined search space
with systematic retesting of all homologous proteins, per-
mit comparisons between interacting protein pairs. Net-
work views of our data identify shared and distinct PPIs
between HTLV-1 and HTLV-2. (Figure 2).
We found 34 human proteins that bind HTLV-1 Tax
protein, but not the HTLV-2 Tax homolog (Figure 2 and
Additional file 1: Table S4). Consistent with its intrinsi-
cally disordered conformation and pleiotropic activities
[26], specific HTLV-1 Tax interactors include proteins
associated with a range of distinct cellular functions such
as transcription regulation (ETV4, RFX4, MyEF2,
ZNHIT4, ZMAT1 and HOXB9), cell apoptosis (TRIP6
and CRADD), protein degradation (WDFY3 and
PSMA1), and microtubule cytoskeleton (KIF9, KRT6A
and KTR8).
We also found 26 HTLV-2 Tax interactors that did not
interact with HTLV-1 Tax, including cell cycle proteins
(Cep70, MAD1L1 and SSX2IP), transcription factors
(NFKB activating protein, ZBTB16 and SOX5) and pro-
teins involved in the endosomal-lysosomal system
(AP4M1 and GCC1) (Figure 2 and Additional file 1:
Table 1 Topological features of viral targets
Viral
Targets
Whole
Network
P-value Random
Sources
Degree 13.75 3.79 2.53E-
14
13.93
CPL 3.09 4.38 < 1E-
320
3.07
Betweenness 12443 2208 6.14E-
14
12646
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Page 4 of 20Table S4). Considering the differential oncogenic poten-
tial of the two HTLV viruses [9] and the central roles of
their Tax proteins, these PPIs could shed light on
mechanisms of cellular transformation by the Tax
oncoprotein.
We have identified 10 novel HBZ binding proteins (Fig-
ure 2) including the homeobox transcription factor
HOXD3; two RNA binding proteins, PCBP1 involved in
restricting viral infections [27] and RNPS1, that can induce
genomic instability when overexpressed [28]. Consistent
with its association with transcriptional repression, we also
found that HBZ interacts with MYST2, a member of the
largest family of histone acetyltransferase enzymes, impli-
cated in the regulation of DNA synthesis [29]. We also
identified 8 novel APH-2 interactors (Figure 2 and Addi-
tional file 1: Table S2) including USF2, a member of the
basic helix-loop-helix (bHLH) leucine zipper family of
t r a n s c r i p t i o nf a c t o r st h a tm a yp l a yar o l ei nl a t ev i r a l
mRNA transcription [30]; VPS37A, a subunit of the mam-
malian endosomal sorting complex ESCRT-1 that have
been shown to play a role in HIV-1 budding [31]; and
NP54, a member of the nucleoporin complex that have
been shown to bind HIV-1 Vpr and to play a critical role
in the nucleocytoplasmic transport of viral preintegration
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Figure 2 HTLV 1 and 2 virus-host Y2H PPI network. Big diamonds: viral ORFs, with HTLV-1 and HTLV-2 in blue and light blue, respectively.
Small circles: Human ORFs, thin links: Y2H interactions; thick links: MAPPIT confirmed interactions. Human ORFs are colored according to
transactivation assay results: green - down-regulation, red - up-regulation, dark red - stronger up-regulation, light green - weaker down-
regulation.
Simonis et al. Retrovirology 2012, 9:26
http://www.retrovirology.com/content/9/1/26
Page 5 of 20complex [32]. Interestingly, we did not find any common
interactor between HBZ and APH-2. The functions of
these new HBZ and APH-2 associations with cellular fac-
tors remain to be further characterized.
Comparison with known data
Databases dedicated to virus-host PPIs (VirHostNet and
VirusMint) contain only few PPI related to HTLV
viruses. We thus manually curated the literature and
found that most of host factors, which have been
demonstrated to interact with HTLV proteins, concern
the highly investigated HTLV-1 Tax (122/147) (Addi-
tional file 1: Table S5). The overlap between our study
and known data is sparse (3 proteins: Nup62, MAD1L1
and Cdc23 - Figure 4A), not surprising given the use of
dissimilar methods, clones, and search spaces. We inte-
grated our dataset with current literature data on known
human-HTLV PPIs and highlighted host factors inter-
acting with at least two different viral proteins (Figure
4B). As examples, HTLV-1 HBZ, Tax and HTLV-2
APH-2 interact with CREB. Both HTLV-1 HBZ and Tax
proteins interact with AP-1, CBP/p300, CREB, ATF and
p65 NFB transcription factors. However, interaction
with these host factors drives opposite effects, as HBZ
and APH-2 are involved in the repression of HTLV-
transcription and are always expressed in leukemic cells
[33,34].
Enrichment of viral targets for biological pathways
The immediate human targets of HTLV proteins found
here were not significantly enriched for annotated path-
ways in the Kyoto Encyclopedia of Genes and Genomes
(KEGG) [35], i.e. the number of proteins belonging to a
specific pathways is not significantly higher than random
expectation, probably because of the limited number of
human targets. To improve sensitivity, we also analyzed
second-degree interactors, those human proteins in the
human-human PPI network [14] that interact with
human targets of viral proteins. Proteins associated with
apoptotic pathways, Notch signaling, cell cycle, ubiquitin
mediated proteolysis, as well as proteins involved in sev-
eral human cancers including chronic myeloid leukemia,
were overrepresented compared to random expectation
(Table 2).
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Page 7 of 20For each enriched KEGG pathway is given the pathway
identifier in the KEGG database (Pathway ID), the num-
ber of observed proteins belonging to the considered
pathway (Observed), the number of proteins in the path-
way expected at random (Random), the ratio between the
number of observed proteins and the expected number
(Odds Ratio), the false discovery rate (FDR), and the cor-
rected FDR (FDR-Corr)
Apoptotic pathway
In an apoptotic pathway sub-network, KEGG analysis
highlighted the tumor necrosis factor (TNF) receptor and
the AKT/PI3K signaling pathways as potential targets for
HTLV proteins. In this network HTLV Tax and Rex pro-
teins are closely linked to the Akt/PI3K and mitochon-
drial apoptotic pathways. We identified interactions
between HTLV Tax proteins and nitric oxide synthase 3
(NOS3), hepatocyte growth factor-regulated tyrosine
kinase substrate (HGS), Ewing sarcoma breakpoint
region 1 (EWSR1) and glucose transporter-4 (SLC2A4)
proteins. KEGG analysis indicated that phosphatidylino-
sitol-3-kinase (PI3K), BCL2-antagonist of cell death
(Bad), and DNA fragmentation factor alpha (DFFA) pro-
teins are second-degree targets of HTLV Tax proteins
(Figure 5). We also found that the HTLV Rex proteins
interact with DLC2 (for dynein light chain 2), able to reg-
ulate cell death-inducing functions of pro-apoptotic pro-
teins Bim (Bcl-2-interacting mediator of cell death) and
Bmf (Bcl-2-modifying factor). HTLV Rex proteins are
nuclear-localizing proteins well known to drive post-
transcriptional export of viral mRNAs from the nucleus
to the cytoplasm [36-38]. Besides its interaction with the
cellular export factor CRM1 [39], functional relationship
between Rex proteins and their cellular partners have not
been fully investigated. Interaction between Rex proteins
and DLC2 may shed light on a new role of Rex in the
apoptotic pathway. To assess the subcellular localization
of Rex1 and DLC2, we transfected HeLa cells with
expression vectors for Rex1-GFP and Flag-tagged DLC2.
Cells were stained by anti-flag antibody followed by
Alexa546-conjugated secondary antibody and a far-red
fluorescent DNA dye (DRAQ5) for nuclear staining.
Consistent with previous reports [40-42], DLC2 was
found exclusively in the cytoplasm (Figure 6A, DLC2);
and Rex-GFP was localized in nucleolar foci (Figure 6A,
Rex1-GFP). Co-expression of Rex1-GFP and Flag-DLC2
provoked a change in the localization of DLC2 with two
patterns being observed. DLC2 was localized in the cyto-
plasm as well as in nuclear foci (Figure 6A, DLC2 +
Rex1-GFP, Alexa546). It thus appeared that coexpression
with Rex1 directs DLC2 in nucleolar foci as revealed by
the good match of the green (Rex1-GFP) and orange
(Flag-DLC2) fluorochromes. We conclude that HTLV
Rex proteins might interfere with the anti-apoptotic
activities of DLC2 in HTLV infected cells.
We also identified TNF receptor-associated factor type 2
(TRAF-2) as a central protein mediating interactions
between HTLV proteins, TNF receptor (TNFR) signaling,
and the Akt/PI3K survival pathway (Figure 5). We found
that TRAF2 directly binds HTLV-2 Gag and is also a sec-
ond-degree interactor of HTLV Tax and Rex proteins.
Depending on its interacting partners, TRAF2 signals
drive contradictory cellular responses. Direct binding to
the cytoplasmic domain of TNFR2, which does not con-
tain a death domain, can trigger NFB and JNK activation,
but TRAF2 also indirectly mediates the signal from a
death domain containing receptors such as TNFR1 via
interaction with FADD and TRADD pro-caspases adaptor
factors [43]. Retroviral infection is frequently associated
with elevated TNFa, and cell lines derived from ATL
patients show sensitivity to TNF-related apoptosis [44].
Gag protein could target TRAF2 for proteasomal
Table 2 KEGG pathways enriched in secondary viral interactors
Pathway Name Pathway ID Observed Random Odds Ratio FDR FDR-Corr
Apoptosis hsa04210 6 1.82 3.31 1.3E-04 1.9E-02
Cell cycle hsa04110 10 2.87 3.48 3.6E-04 4.8E-02
Chronic myeloid leukemia hsa05220 8 1.59 5.03 2.1E-05 3.2E-03
Colorectal cancer hsa05210 7 2.13 3.28 9.3E-05 1.4E-02
ErbB signaling pathway hsa04012 7 1.67 4.19 6.3E-05 9.5E-03
Glioma hsa05214 7 0.76 9.26 6.2E-05 9.3E-03
Huntington’s disease hsa05040 6 0.34 17.41 < 2.5E-06 < 3.8E-04
Insulin signaling pathway hsa04910 10 2.06 4.86 1.2E-04 1.8E-02
Melanoma hsa05218 4 0.64 6.27 1.4E-04 2.0E-02
Notch signaling pathway hsa04330 4 1.82 2.20 < 2.5E-06 < 3.8E-04
Olfactory transduction hsa04740 4 0.16 25.66 < 2.5E-06 < 3.8E-04
Prostate cancer hsa05215 5 1.04 4.79 2.9E-04 4.3E-02
Ubiquitin mediated proteolysis hsa04120 10 3.02 3.31 2.0E-04 2.9E-02
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Page 8 of 20degradation, thereby facilitating sensitivity to TNFa-
induced cell death. To investigate this possibility we co-
expressed GFP tagged HTLV-2 Gag, Flag tagged TRAF2
and a Myc-Ubiquitin expressing vectors. The presence of
HTLV-2 Gag reduced TRAF2 protein levels (Figure 7A,
aFlag compare lanes 1 and 2; and lanes 3 and 4), and
degradation of TRAF2 correlated with a reduction of
Myc-ubiquitylated proteins (Figure 7A, aMyc compare
lanes 3 and 4) suggesting that the TRAF2-E3 ubiquitin
ligase activity was also affected by the presence of HTLV-2
Gag protein. The degradation of TRAF2 could be blocked
by preincubating cells with proteasome inhibitor MG132
(Figure 7B). Together these data indicate that HTLV-2
Gag induces proteasomal degradation of TRAF2.
Cell cycle
Cell cycle is a tightly regulated cellular process targeted
by transforming viruses to modulate cell division and
proliferation. HTLV-1 Tax has been shown to bind cell
cycle key regulators including cyclins-D1, D2 and D3,
cyclin-dependent kinases (CDK) 4 and 6; and CDK inhi-
bitor p16INK4a, to influence T lymphocyte G1-S pro-
gression [45-47]. HTLV-1 Tax also interacts with DNA
repair and checkpoint proteins including checkpoint
kinases (Chk) 1 and 2 and members of the mitotic spin-
dle-assembly checkpoint (MAD1L1, MAD2L1 and
MAD2L2) [48] (Figure 8). Common features in cell
cycle regulation between HTLV-1 and -2 Tax proteins
shown here, include their direct interaction with the
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Figure 5 Targeting of apoptotic pathway by viral proteins.( A) Schematic representation of PPIs. Big diamonds: viral ORFs, with HTLV-1 and
HTLV-2 in blue and light blue, respectively. Small circles: human ORFs with green representing membership of the apoptotic pathway. Grey links:
human-human PPIs; blue links: virus-human PPIs.
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Page 9 of 20MAD complex and with the anaphase-promoting com-
plex or cyclosome (APC/C) via Cdc23 protein; and their
indirect connection to similar cell cycle proteins such as
Cdc27, Cdc2, PCNA and SMADs proteins (Figure 8).
O n ed i f f e r e n c eh i g h l i g h t e dh e r ei st h ei n t e r a c t i o no f
HTLV-1 Tax, and not HTLV-2 Tax, with the 26 protea-
some subunit PSMA1, which could link HTLV-1 Tax to
the minichromosome maintenance complex (MCM), the
polo-like kinases (Plk) or the CDK-activating kinase
complex (CCNH) (Figure 8). All these newly identified
interactions should be validated in appropriate cell lines
such as human hematopoietic stem cells (HSCs) pre-
viously used to demonstrate differences between Tax1
and 2 in cell cycle arrest in G0/G1 [9,49].
DRAQ5 GFP Alexa546 Merged
DLC2
Rex1-GFP
DLC2
+
Rex1-GFP
B
A
Figure 6 HTLV-1 Rex and DLC2 co-localize in nucleolar foci.( A) HeLa cells were transfected with expression vectors for Rex1-GFP and Flag-
DLC2 as indicated. Twenty-four hours post-transfection, cells were labeled with anti-flag M2 mouse antibody followed by alexa546-conjugated
anti-mouse secondary antibody. Cells were stained with the far-red DNA marker DRAQ5 and analyzed by confocal microscopy. Merge
corresponds to the simultaneous acquisition of all three fluorochromes. (B) Fluorescent intensities were plotted along the red line segments. The
green and orange lines in the profile correspond to the relative intensities of GFP and Alexa 546.
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Page 10 of 20Ubiquitin-mediated proteolysis pathway
We identified cellular E2 ubiquitin-conjugating enzymes
UBE2I and UBE2N or UBC13; and E3 SUMO-protein
ligases PIAS (protein inhibitor of activated STAT) 1, 2
and 4. Both types of enzymes have been previously
shown to play a role in Tax-mediated NF-kB activation
[50,51]. KEGG analysis also highlighted E3 ubiquitin
ligases (CDC23, TRAF2 and TRAF6), which interact
with HTLV proteins and which may play important
roles in induced perturbations of the proteasomal path-
way. CDC23 is a member of the anaphase promoting
complex/cyclosome (APC/C, including CDC23), an E3
ubiquitin ligase that controls metaphase to anaphase
transition [52-54]. TRAF proteins contain a RING finger
domain, a domain that can simultaneously bind ubiqui-
tination enzymes and their substrates [55,56] (Figure 9).
HTLV-1 Tax might also provide a bridge to the protea-
some by disrupting the interaction between an E3 ubi-
quitin ligase and its substrate, illustrated by the
inactivation by Tax of the A20-Itch E3 ligase complex,
potentially leading to a permanent activation of tumor
necrosis factor (TNF) receptor (TNFR) signaling [57].
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Page 11 of 20Most eukaryotic cellular proteins are selectively
degraded by the ubiquitin-proteasome system [58].
Numerous infectious and cancer agents induce aberra-
tions in the proteasomal pathway, and several inhibitors
have been proposed as promising therapies [59-62].
Effective therapy faces challenges, as the activity of the
proteasome is subjected to multiple regulation, and the
selection of precise targeted proteins involves highly
specific E2 and E3 ubiquitin enzymes [63].
Notch pathway
The highly conserved Notch signaling pathway regulates
diverse cell fate decisions, including differentiation, prolif-
eration, communication and specification. Several mem-
bers of the Notch signaling pathway, including Numb [64],
dishevelled (Dvl) proteins [65], cAMP-response element-
binding protein (CREB)-binding protein (CREBBP or
CBP) [66,67], and p300 [68], are targeted by HTLV Tax,
Rex, Hbz, Gag and Pol proteins (Figure 10). It has been
recently shown that the g-secretase inhibitor (GSI)
reduced tumor cell proliferation and tumor formation in
an Adult T-cell Leukemia animal model [69]. To directly
assess the involvement of the Notch pathway in viral infec-
tion, we treated an HTLV-1 transformed cell line (MT4)
with a g-secretase inhibitor (GSI) (L-685,458) [70] and
tested whether inhibition of the Notch pathway could
affect HTLV-1 expression in MT4 cell line. Interestingly,
we showed by quantitative RT-PCR, that inhibition of the
Notch pathway significantly lowered HTLV-1 HBZ (p <
2.1E-5), Gag (p < 0.04) and Tax1 (p < 0.003) expression in
MT4 cells (Figure 10B), sug g e s t i n gt h a tG S Ic o u l db ea
new class of retroviral replication inhibitors.
Conclusion
HTLV-1 and HTLV-2 are closely related human deltare-
troviruses that have a similar genomic organization and
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Page 12 of 20share a high degree of sequence homology. Both viruses
are able to immortalize T lymphocytes in vitro.I nc o n -
trast to HTLV-1, HTLV-2 has not been conclusively
associated with any known human disease. Most com-
parative studies to identify molecular differences
between HTLV-1 and -2 are based on literature data on
the viral encoded oncoproteins Tax-1 and Tax-2 activ-
ities (reviewed in [9,10])
Several global analyses of virus-host protein-protein
interaction networks have led to interesting hypotheses
about network topological properties and about shared
target human proteins and pathways [8,21]. Such statis-
tical analyses were done on collections of literature-
curated information and thus are biased in several ways.
G i v e na ni n h e r e n t‘inspection bias’ some proteins are
more heavily studied than others, with selection biased
towards ‘interesting’ processes, diseases or potential
applications, leading to a non-homogeneous representa-
tion of different viruses and proteins. Moreover, collec-
tions from public databases are constituted of a
heterogeneous assortment of different assays, clones,
variants, experimental conditions, or inferences. Com-
paring data obtained from different experiments severely
limits the applicability of statistical analysis.
H e r e ,w ei d e n t i f i e db yas y s tematic stringent high-
throughput methodology, cellular interacting partners
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Tax, Rex, Env, Pol, Gag, and APH-2 (Figure 2 and Addi-
tional file 1: Table S2), providing the first attempt at a
large scale comparative analysis of HTLV-1 and -2 host
factors interactome with homogenous data. Although
our data show several differences between HTLV-1 and
-2 at the level of individual interactions with cellular tar-
gets, the findings do not show that they target distinct
pathways. Cellular factors interacting with HTLV-1 and
HTLV-2 seem to be involved in similar pathways
(Apoptosis, Notch signaling, cell cycle, ubiquitin
mediated proteolysis,...), but in different ways (Table 2
and Figures 5, 6, 7, 8, 9 and 10). This study identified
many new host factors, raises new hypotheses and
demonstrates the usefulness of the approach by experi-
mental validation of some specific examples; but the
incompleteness of the data does not allow us to build
predictive models. Interactome maps presented here are
incomplete for at least three reasons. First, the human
ORFeome v3.1 collection we used covers only ~50% of
the human proteome and does not include variants. Sec-
ond, yeast two-hybrid, like any PPI assay, captures only
a portion of protein-protein interactions [18]. Third,
interactome screens are rarely conducted to saturation,
i.e. yielding all possible interactions under the given
conditions. To identify most physical interactions and to
be able to build comprehensive systems biology models
would require combining several assays, with each assay
conducted to saturation, using the most complete col-
lection of clones, including variants, and under a wide
range of experimental conditions. In addition, all inter-
actions should be functionally validated, localized and
their dynamics studied. Current efforts to map protein-
protein interactions should hopefully lead to near com-
plete maps for several organisms in the future.
In conclusion, our experimental identification of 166
PPIs involving 10 HTLV-1 and -2 retroviral proteins
with 122 human proteins extends and complements
existing data on human-viral protein interactions
[8,15,16,21,71,72].
We also identify and discuss common and distinct host
cellular proteins targeted by HTLV-1 and -2 in relations
with several cellular pathways, and we present innovative
targets for further investigation of HTLV-induced net-
work perturbations and illustrate the usefulness of this
dataset by further investigation of Rex-DLC2, TRAF2-
Gag and the involvement of the Notch pathway.
Availability of supporting data
All protein-protein interaction data were submitted to
VirHostNet http://pbildb1.univ-lyon1.fr/virhostnet.
Interactions resulting from this study are provided in
MIMIX specifications http://mibbi.org/index.php/Pro-
jects/MIMIx in Additional file 2.
Methods
Cloning of HTLV-1 and HTLV-2 ORFeomes
HTLV-1 and HTLV-2 ORFeomes were cloned by Gateway
recombination methodology (Invitrogen)u s i n ga sP C R
templates the following DNA clones obtained through the
AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH: MT-2, ATK, pH6 B 3.5 and pH6 B
5.0. DNA clones MT-2 [73], ATK [74], pH6 B 3.5 and
pH6 B 5.0 from Dr. Irvin Chen [75,76]. Clones pcDNA-
SP1 was obtained from Dr. Mesnard [77], Rex1-GFP from
Dr. Bex [42] pSG5-APH2 from Dr. Mahieux [34], PcDNA-
1-Tax1 from Dr. Bex [78] and BC20.2 from Dr. Green
[79]. The specific primers for each ORF contained AttB1.1
and AttB2.1 Gateway recombination sites forward
5’GGGGACAACTTTGTACAAAAAAGTTGGC and
reverse 5’GAGAGTTAGTGGCCCGCAGGTCGGGGGA,
allowing recombinational cloning into the spectinomycin
resistant donor vector pDONR223 by BP clonase
(Invitrogen).
All full-length and partial retroviral ORFs (rvORFs)
were transferred by LR cloning into pDB-dest and pAD-
dest-CYH [19] to generate yeast expression vectors for
DB-rvORF and AD-rvORF fusion proteins. The rvORFs
were also transferred into Gateway MAPPIT vectors for
the expression of chimeric bait and prey in mammalian
cells [20]. For other functional assays, the human ORFs
encoding proteins identified in Y2H experiments were
transferred from their corresponding entry clones into
pDEST-Flag destination vectors [80].
High-throughput yeast two-hybrid
AD-rvORF and DB-rvORF yeast expressing vectors were
transformed into two different MATa and MATa strains
of yeast, respectively: MaV103 and Y8800 for all AD-ORFs
and MaV203 and Y8930 for all DB-ORFs. Transformed
yeast cells were spotted on solid synthetic complete (Sc)
media lacking tryptophan (Sc-T) to select for AD-rvORF
clones, or lacking leucine (Sc-L) to select for DB-rvORF
clones. Growing colonies were cultured in liquid Sc-L or
Sc-T media and stored in glycerol for subsequent use. To
eliminate autoactivator baits that activate reporter genes in
the absence of AD plasmids, all DB-ORFs in Mav203
strain or Y8930 were individually tested for auto-activation
by growth on solid SC-L-H medium containing 20 mM
(Mav103 strain) or 2 mM (Y8930 strain) 3-amino-triazole
(3-AT). Aliquots of AD-rvORF transformed yeast were
pooled to generate the AD-rvORF library.
Yeast two-hybrid screening was as described [14].
Yeast matings were performed with Mav103 and
MaV203 or with Y880 and Y8930. Each of 12,212 DB-
ORFs MATa yeast strains of the human ORFeome ver-
sion 3.1 [17] was mated with a pool of MATa yeast
strains containing individual retroviral AD-rvORFs. The
screen was also done in the reciprocal orientation,
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the 12,212 human AD-ORFs pooled into 65 mini-
libraries [14]. Diploid cells were selected on solid media
Sc-L-T-H (containing 20 mM 3-AT for the MaV strain),
and de novo autoactivators were eliminated using the
counter-selectable marker CYH2 [19]. Positive colonies
were picked for PCR amplification and identification of
interacting proteins by sequencing of the respective AD-
and DB-ORFs.
Each human protein found to interact with viral pro-
teins was individually retested against all homologous
proteins in the HTLV viruses. To this end, we mated
MATa (Mav203 or Y8930) and MATa (Mav103 or
Y8800) yeast cells containing individual DB and AD
fused to interacting human and retroviral ORF, respec-
tively. Resulting diploid cells were tested for activation
of multiple reporter genes [14].
MAPPIT assay
The mammalian protein-protein interaction trap (MAP-
PIT) [20] fuses a bait to a STAT recruitment-deficient,
homodimeric cytokine receptor, while the prey is coupled
to the C-terminal STAT recruitment portion of the
gp130 receptor. HEK293T cells maintained in DMEM
medium supplemented with 10% of fetal bovine serum,
2 mM glutamine, 100 U/ml of penicillin and streptomy-
cin were cotransfected with a STAT-responsive luciferase
reporter, the bait, and the prey or control constructs.
Twenty-four hours post-transfection, cells were stimu-
lated with erythropoietin or left untreated for an addi-
tional 24 hours. Luciferase activity was measured from
two independent transfection experiments in triplicate.
Each interaction pair was tested in both orientations. The
“Experiment to Control Ratio” (ECR) was computed as
the ratio of “bait + prey” (BP) signal over “bait + irrele-
vant prey” (BIP) or “prey + irrelevant bait” (PIB) signals.
To account for the variability of the raw data, Fieller’s
confidence interval at 95% for the ratios BP/BIP and BP/
PIB was computed from the raw induction values. Het-
erogeneous variances were assumed, using the test by
Tamhane and Logan, inverted according to Fieller’s theo-
rem [81,82]. This test was run with the R statistical pack-
age ‘pairwiseCI’. For a trial to be considered positive, the
lower bound of the ECR confidence interval has to be >
= 3 for both BP/BIP and BP/PIB ratios.
Transactivation assay
The plasmid pHTLV1LTR-Luc, containing a luciferase
reporter gene under the control of the HTLV-1 LTR
promoter, a renilla luciferase control vector, and plas-
mids expressing HTLV-1 Tax and each human ORF
found to interact with these viral proteins, were co-
transfected into HEK293T cells by the calcium phos-
phate method. The LTR luciferase construct was
obtained by subcloning HTLV-1 LTR promoter (a gift
from F. Bex [78]) into pGL3-basic vector (promega).
Twenty-four hours post-transfection, cells were washed
three times with PBS, lysed, and relative luciferase activ-
ities determined from two independent transfection
experiments in triplicate. We computed a paired t-test
to assess the difference of the means between samples
with and without the human interactor. For a trial to
be considered positive, the relative luciferase activities
have to be > = 2 or < = 0.5, and the p-value of the
t-test < 0.05.
Effect of SPG21 and FANCG knockdown on viral promoter
activation
HTLV-1 LTR promoter fused to firefly luciferase was
transduced into Jurkat cells using the pREP10 vector (Invi-
trogen). Selection with hygromycin B (100 μg/ml) was
employed to obtain stable transfectants (Jurkat-LTR-Luc
cells). Lentiviral particles expressing a control shRNA and
validated shRNA targeting various sequences of the
SPG21 and FANCG mRNAs [83] were prepared as
d e s c r i b e d[ 8 4 ] .s h R N A sw e r eo b t a i n e df r o mS i g m a
(TRCN0000300854, TRCN0000304152, TRCN000
0304153, TRCN0000082858, TRCN0000082859, TRCN00
00082860, TRC1). Infected Jurkat-LTR-Luc cells were
selected using puromycin (10 μg/ml). Jurkat-LTR -Luc
cells stably expressing shRNA for SPG21 (Jurkat-LTR-
shSPG21_1 to 3 and Jurkat-LTR-FANCG_1 to 3) and con-
trol cells (Jurkat-LTR-luc expressing a sh control) were
cultured for 24 hours, and luciferase activities were mea-
sured. An aliquot was used to assess cell viability using a
WST1 kit as described by the manufacturer (Roche).
Differences of expression were assessed with one-tailed
Student’s t-test on triplicate experiments.
Topological analysis
We computed the mean degree, characteristic path
length (CPL) and betweenness centrality in an unbiased
human-human PPI network [14] for the 131 human
proteins identified in the HT-Y2H screen. The CPL of a
node (protein) is the mean of the shortest paths from all
nodes to the considered node in the network. We used
Mann-Whitney U-test to compare the degree, CPL and
betweenness distributions of the 131 viral targets to the
whole network.
KEGG pathway analysis
Definitions of pathways came from the KEGG database
(September 2008). We used Fisher’s Exact Test to deter-
mine pathway enrichment of direct targets of viral pro-
teins. To evaluate the significance of indirect targets
enrichment, we ran 100,000 simulations where we rando-
mized the identity of the direct targets. The interactors of
these targets were identified in the unbiased PPI network
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the resulting distribution compared to the observed
counts. An empirical False Discovery Rate (FDR) deter-
mined the significance of the enrichment, with the FDR
computed as the proportion of random trials giving at
least the observed number of indirect targets in the con-
sidered pathway. The FDR was corrected for multiple
testing using the Bonferroni correction. Pathways with a
FDR Corr < 0.05 and at least four observed proteins were
taken as significant.
To avoid study bias inherent to literature curation, we
used the CCSB-HI1 network [14] to compute the enrich-
ment of indirect targets for KEGG pathways. The plotted
networks (Figures 5, 8, 9 and 10) were built from a litera-
ture-curated interaction (LCI) network to show the most
complete information. The LCI network is the union of
human PPIs from BIND [85], DIP [86], HPRD [87],
INTACT [88], and MINT [89] interaction databases
(April 2007).
To construct sub-networks (Figures 5, 8, 9 and 10) for
each pathway, direct targets of viral proteins belonging to
the corresponding KEGG pathway, and direct targets
linked to viral proteins were selected as “seeds”. Interac-
tors of these seeds in the human-human LCI network and
belonging to the considered pathway were then selected as
indirect targets, and all interactions between seeds and
indirects targets were plotted, along with our virus-human
PPI network. All network figures were constructed with
Cytoscape [90].
Co-expression of TRAF2 and gag
HEK293T cells were cultured in a humidified atmo-
sphere with 5% CO2 at 37°C in DMEM supplement
with 10% of fetal bovine serum and antibiotics.
HEK293T cells were transfected using the calcium phos-
phate method [91]. In some cases, cells were pretreated
with proteasomal inhibitor MG132 for 24 hr; washed in
ice-cold PBS and lysed in IPLS buffer (1% NP-40, 10%
glycerol, 120 mM NaCl, 20 mM Tris pH 7.5, 2 mM
EDTA, and complete protease inhibitor cocktail
(Roche)). Cell lysates were analyzed by Western blot
using an anti-Flag M2 (Sigma), anti-GFP (abcam) or
anti-Myc (Santa Cruz Biotechnology) antibodies.
Confocal microscopy
HeLa cells were transfected with expression vectors for
Rex1-GFP and Flag tagged DLC2 using Lipofectamine
2000 according to the manufacturer instructions (Invitro-
gen). Twenty four hours post-transfection, cells were
fixed in 4% formaldehyde (20 minutes at room tempera-
ture), permeabilized with 0.5% triton X-100, and incu-
bated with anti Flag M2 antibody (Sigma) followed by
Alexa546 -coupled anti-mouse secondary antibody (Invi-
trogen). After nuclear staining with DRAQ5 (Invitrogen),
and fixing with mounting medium (fluoromount, Sigma),
cells were analyzed using a Zeiss fluorescence confocal
microscope (Carl Zeiss Microscopy).
Inhibition of notch signaling
HTLV-1 transformed cell line (MT4) from Dr. Douglas
Richman [92] was obtained through the AIDS Research
and Reference Reagent Program, Division of AIDS,
NIAID, NIH. MT4 cells were cultured in RPMI supple-
mented with 10% fetal bovine serum and antibiotics.
MT-4 cells were treated for 48 hours with or without g-
secretase inhibitor (L-685,458) [70] at 1 μM. Total
RNAs were then isolated by Trizol method, subjected to
DNase treatment and cDNAs synthesized using the
RevertAid First Strand cDNA Synthesis kit according to
the manufacturer instructions (Fermentas). Quantitative
real-time PCR for GAPDH, HBZ, Gag and Tax expres-
sion was on a StepOne instrument (Applied Biosystem)
using SYBR green dye (Eurogentec). Viral mRNA
expression data are calculated relative to GAPDH
mRNA expression data as 2^(CT(GAPDH)-CT(HBZ/
Gag/Tax)) over three times triplicate experiments for
each gene, and differences were assessed through one-
tailed Student’s t-test.
Additional material
Additional file 1: Table S1. List of viral ORFs. Table S2. experimental
results. Table S3. Host factors regulating HTLV-1 LTR promoter activation
by Tax. Table S4. Human proteins interacting with Tax viral proteins.
Table S5. List of HTLV-1 and -2 host factors extracted from public
database (Virhosnet) or literature search. Table S6. Viral targets degrees
HTLV_human_PPIs_MIMiX.txt PPIs experimental results - MIMiX standard.
Additional file 2: PPIs experimental results in MIMiX standard
specifications.
Abbreviations
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virus type-2; HIV-1: Human immunodeficiency virus type 1; PPI: Protein-
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